Target Trial Emulation of Metformin for Dementia Prevention in All of Us: Robustness to Cohort and Confounder Definitions
- 1MIT
Abstract
Metformin use has been associated with a lower risk of incident dementia than other antidiabetics. We perform target trial emulation and causal competing risk analysis in the NIH All of Us (AoU) Research Program database, contrasting the effects of metformin and sulfonylurea initiation on dementia onset and death without dementia. AoU's social and behavioral health data allowed us to test robustness to excluding such confounders, and we further adjusted for calendar year effects and prior antidiabetic exposure, using both semiparametric Cox proportional hazards (PH) models and nonparametric models. Under stabilized inverse propensity score of treatment weighting, metformin was associated with a substantially lower risk of death (hazard ratio [HR]: 0.61, 95% CI: [0.49, 0.75]) and a lower incidence of dementia (HR: 0.90, 95% CI: [0.82, 1.02]). Estimated HRs were closely aligned with estimates obtained in the UK primary care and US Mass General Brigham health systems. This finding was robust to the inclusion of participants without a type 2 diabetes diagnosis at baseline and to the consideration of different covariate sets in the propensity score model, supporting metformin as a promising candidate for dementia prevention and motivating prospective validation.
Related
- Metformin at the Time of COVID‐19 Infection and Risk of Long COVID: A Target Trial Emulation Study
- Associations of mortality and sepsis after GLP-1 receptor agonist initiation versus SGLT2 inhibitor or metformin initiation in people with HIV, overweight or obesity, and type 2 diabetes: A target trial emulation
- Shortening of central venous catheter time in men with hematological and oncological diseases for prevention of central venous catheter-related bloodstream infections: a target-trial-emulation study
- Confounder-Adjusted Plasma Proteomics Identify Robust Protein Signatures in Sepsis Across Two Independent Perioperative Control Cohorts
- Toward Endotype-Based Bronchopulmonary Dysplasia: Evolving Definitions and the Role of Translational Models
BibTeX
@misc{charpignon2026target,
title = {{Target Trial Emulation of Metformin for Dementia Prevention in All of Us: Robustness to Cohort and Confounder Definitions}},
author = {M.-L. Charpignon and T. Shnitzer and A. Iraqui and D. F. Pace and M. Maddah and C. Uhler},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.02.26367055},
url = {https://www.medrxiv.org/content/10.64898/2026.11.02.26367055v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Target Trial Emulation of Metformin for Dementia Prevention in All of Us: Robustness to Cohort and Confounder Definitions
AU - M.-L. Charpignon
AU - T. Shnitzer
AU - A. Iraqui
AU - D. F. Pace
AU - M. Maddah
AU - C. Uhler
PY - 2026
DA - 2026/11/02
PB - medRxiv
DO - 10.64898/2026.11.02.26367055
UR - https://www.medrxiv.org/content/10.64898/2026.11.02.26367055v1
AB - Metformin use has been associated with a lower risk of incident dementia than other antidiabetics. We perform target trial emulation and causal competing risk analysis in the NIH All of Us (AoU) Research Program database, contrasting the effects of metformin and sulfonylurea initiation on dementia onset and death without dementia. AoU's social and behavioral health data allowed us to test robustness to excluding such confounders, and we further adjusted for calendar year effects and prior antidiabetic exposure, using both semiparametric Cox proportional hazards (PH) models and nonparametric models. Under stabilized inverse propensity score of treatment weighting, metformin was associated with a substantially lower risk of death (hazard ratio [HR]: 0.61, 95% CI: [0.49, 0.75]) and a lower incidence of dementia (HR: 0.90, 95% CI: [0.82, 1.02]). Estimated HRs were closely aligned with estimates obtained in the UK primary care and US Mass General Brigham health systems. This finding was robust to the inclusion of participants without a type 2 diabetes diagnosis at baseline and to the consideration of different covariate sets in the propensity score model, supporting metformin as a promising candidate for dementia prevention and motivating prospective validation.
ER -